Avalon GloboCare’s Laboratory Services MSO Signs Exclusive In-Network Lab Services Agreement Providing Significant Expansion Opportunity into 21 States
July 19, 2023 09:00 ET
|
Avalon GloboCare Corp.
MSA Signed with GeneX Laboratory, an In-Network Laboratory Licensed in Multiple States Including Medicare and Medicaid Laboratory Services MSO will be the Exclusive Testing Provider for Toxicology...
Avalon GloboCare Provides Update on New Commercial Strategy
July 10, 2023 09:00 ET
|
Avalon GloboCare Corp.
Company Continues to Implement Major Change in Strategy Focused on Acquiring and Operating Accretive Revenue Generating Laboratories and Related Commercialized Products Company Plans on Developing...
Avalon GloboCare Reports Laboratory Services MSO Revenue of $14.7 Million and Net Income of $6.3 Million in 2022
April 27, 2023 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision...
Avalon GloboCare Announces Commercial Launch of KetoAir Breathalyzer at the KetoCon Austin 2023 Conference
April 17, 2023 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision...
Avalon GloboCare Signs Agreement with Qi Diagnostics to Exclusively Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, U.K. and European Union
April 11, 2023 09:00 ET
|
Avalon GloboCare Corp.
Commercialization-ready; initially targeting diabetes reversal and weight management markets Coupling diagnostic tools with advanced artificial intelligence software for nutrition management ...
Avalon GloboCare to Participate in the 35th Annual Roth Conference
March 03, 2023 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technology, cellular therapy...
Avalon GloboCare Announces Closing of Strategic Investment in Laboratory Services MSO, a Leading Clinical Diagnostics and Reference Laboratory Company
February 13, 2023 09:00 ET
|
Avalon GloboCare Corp.
Transaction Expected to Be Accretive to Earnings Through Profit Sharing Agreement Adds Strong Clinical Synergies to Existing Avalon Portfolio Marks Launch of New Roll-Up Strategy Targeting...
Avalon GloboCare Announces Issuance of Key U.S. Patent for Multiple Novel QTY-Code Modified Cytokine and Chemokine Protein Receptor Molecules
January 17, 2023 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technologies and...
Avalon GloboCare Appoints Lourdes Felix, CEO of a Premier Addiction Treatment Company, to its Board of Directors
January 11, 2023 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technologies and therapeutics...
Avalon GloboCare Announces the Deployment of Breakthrough Fusion Gene Map Technology
January 03, 2023 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technologies and therapeutics...